These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36156061)

  • 21. Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020.
    Jacobs JA; Zheutlin AR; Derington CG; King JB; Pandey A; Bress AP
    Am J Prev Cardiol; 2024 Mar; 17():100624. PubMed ID: 38125205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.
    Anson M; Zhao SS; Austin P; Ibarburu GH; Malik RA; Alam U
    Diabetologia; 2023 Oct; 66(10):1869-1881. PubMed ID: 37505282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD.
    Gregg LP; Ramsey DJ; Akeroyd JM; Jafry SA; Matheny ME; Virani SS; Navaneethan SD
    Am J Kidney Dis; 2023 Jul; 82(1):53-62.e1. PubMed ID: 36702340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
    Cardoso P; Young KG; Nair ATN; Hopkins R; McGovern AP; Haider E; Karunaratne P; Donnelly L; Mateen BA; Sattar N; Holman RR; Bowden J; Hattersley AT; Pearson ER; Jones AG; Shields BM; McKinley TJ; Dennis JM;
    Diabetologia; 2024 May; 67(5):822-836. PubMed ID: 38388753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study.
    D'Onofrio L; Mignogna C; Carlone A; Bellizzi E; Di Guida M; Moretti C; Zampetti S; Leto G; Maddaloni E; Buzzetti R
    Diabetes Res Clin Pract; 2021 Mar; 173():108681. PubMed ID: 33516784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
    Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.
    Varshney N; Billups SJ; Saseen JJ; Fixen CW
    Ther Adv Drug Saf; 2021; 12():2042098621997703. PubMed ID: 33854754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
    Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
    Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus.
    Zhang J; Van Spall HG; Li L; Khan MS; Pandey A; Thabane L; Bai X; Wang Y; Lip GY; Li G
    Diabetes Metab Syndr; 2023 Jul; 17(7):102804. PubMed ID: 37315473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes.
    Limonte CP; Hall YN; Trikudanathan S; Tuttle KR; Hirsch IB; de Boer IH; Zelnick LR
    J Diabetes Complications; 2022 Jun; 36(6):108204. PubMed ID: 35537891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes.
    Kahkoska AR; Abrahamsen TJ; Alexander GC; Bennett TD; Chute CG; Haendel MA; Klein KR; Mehta H; Miller JD; Moffitt RA; Stürmer T; Kvist K; Buse JB;
    Diabetes Care; 2021 Jul; 44(7):1564-1572. PubMed ID: 34135013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes.
    Luo J; Gabriel N; Korytkowski M; Hernandez I; Gellad WF
    Diabetes Res Clin Pract; 2022 May; 187():109855. PubMed ID: 35346753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team.
    Champion M; Wills Avila G; Garcia AE; Álvarez Delgado FM; Valdez CA
    J Prim Care Community Health; 2024; 15():21501319241231398. PubMed ID: 38353180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes.
    Al-Ozairi E; Irshad M; Taghadom E; Sojan L; Al Kandari J; Alroudhan D; le Roux CW
    Obesity (Silver Spring); 2023 Mar; 31(3):716-723. PubMed ID: 36811241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The new evidence on cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: one step closer to their use in this setting?
    Popovic DS; Koufakis T; Patoulias D; Papanas N
    Expert Rev Clin Pharmacol; 2023; 16(11):1021-1023. PubMed ID: 37864783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.
    Michos ED; Bakris GL; Rodbard HW; Tuttle KR
    Am J Prev Cardiol; 2023 Jun; 14():100502. PubMed ID: 37313358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL
    Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials.
    Rizos EC; Tagkas CF; Asimakopoulos AI; Tsimihodimos V; Anastasiou G; Rizzo M; Agouridis AP; Ntzani EE
    J Diabetes Complications; 2024 Jul; 38(7):108781. PubMed ID: 38833853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.